Literature DB >> 27686281

The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process.

Chung-I Wu1,2,3, Hurng-Yi Wang4, Shaoping Ling1,2, Xuemei Lu2.   

Abstract

Although tumorigenesis has been accepted as an evolutionary process ( 20 , 102 ), many forces may operate differently in cancers than in organisms, as they evolve at vastly different time scales. Among such forces, natural selection, here defined as differential cellular proliferation among distinct somatic cell genotypes, is particularly interesting because its action might be thwarted in multicellular organisms ( 20 , 29 ). In this review, selection is analyzed in two stages of cancer evolution: Stage I is the evolution between tumors and normal tissues, and Stage II is the evolution within tumors. The Cancer Genome Atlas (TCGA) data show a low degree of convergent evolution in Stage I, where genetic changes are not extensively shared among cases. An equally important, albeit much less highlighted, discovery using TCGA data is that there is almost no net selection in cancer evolution. Both positive and negative selection are evident but they neatly cancel each other out, rendering total selection ineffective in the absence of recombination. The efficacy of selection is even lower in Stage II, where neutral (non-Darwinian) evolution is increasingly supported by high-density sampling studies ( 81 , 123 ). Because natural selection is not a strong deterministic force, cancers usually evolve divergently even in similar tissue environments.

Entities:  

Keywords:  cancer evolution; cell population genetics; convergent evolution; intratumor heterogeneity; natural selection

Mesh:

Year:  2016        PMID: 27686281     DOI: 10.1146/annurev-genet-112414-054842

Source DB:  PubMed          Journal:  Annu Rev Genet        ISSN: 0066-4197            Impact factor:   16.830


  29 in total

1.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

Review 2.  A population genetics perspective on the determinants of intra-tumor heterogeneity.

Authors:  Zheng Hu; Ruping Sun; Christina Curtis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-06       Impact factor: 10.680

3.  Reply: Uncertainties in tumor allele frequencies limit power to infer evolutionary pressures.

Authors:  Marc J Williams; Benjamin Werner; Chris P Barnes; Trevor A Graham; Andrea Sottoriva
Journal:  Nat Genet       Date:  2017-08-30       Impact factor: 38.330

4.  Tumorigenesis as the Paradigm of Quasi-neutral Molecular Evolution.

Authors:  Bingjie Chen; Zongkun Shi; Qingjian Chen; Xu Shen; Darryl Shibata; Haijun Wen; Chung-I Wu
Journal:  Mol Biol Evol       Date:  2019-07-01       Impact factor: 16.240

Review 5.  Resolving genetic heterogeneity in cancer.

Authors:  Samra Turajlic; Andrea Sottoriva; Trevor Graham; Charles Swanton
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

Review 6.  Epimutations Define a Fast-Ticking Molecular Clock in Plants.

Authors:  Nan Yao; Robert J Schmitz; Frank Johannes
Journal:  Trends Genet       Date:  2021-05-17       Impact factor: 11.821

Review 7.  Zebrafish Xenograft: An Evolutionary Experiment in Tumour Biology.

Authors:  Rachael A Wyatt; Nhu P V Trieu; Bryan D Crawford
Journal:  Genes (Basel)       Date:  2017-09-05       Impact factor: 4.096

8.  Free-living human cells reconfigure their chromosomes in the evolution back to uni-cellularity.

Authors:  Jin Xu; Xinxin Peng; Yuxin Chen; Yuezheng Zhang; Qin Ma; Liang Liang; Ava C Carter; Xuemei Lu; Chung-I Wu
Journal:  Elife       Date:  2017-12-18       Impact factor: 8.140

9.  A mathematical theory of the transcription repression (TR) therapy of cancer - whether and how it may work.

Authors:  Yuxin Chen; Haijun Wen; Chung-I Wu
Journal:  Oncotarget       Date:  2017-06-13

10.  Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.

Authors:  Guanyou Lin; Richard A Revia; Miqin Zhang
Journal:  Adv Funct Mater       Date:  2020-10-13       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.